Trgovina Monopar Therapeutics Inc. - MNPR CFD
Dodaj med priljubljene- Povzetek
- Zgodovinski podatki
- Dogodki
- Izkaz poslovnega izida
- Bilanca stanja
- Denarni tok
- Lastništvo
Razmik | - | ||||||||
Nočna pristojbina za nakup
Long position overnight fee
Pojdi na platformo | -0.024068% | ||||||||
Nočna pristojbina za prodajo
Short position overnight fee
Pojdi na platformo | 0.001846% | ||||||||
Čas nočne pristojbine | 21:00 (UTC) | ||||||||
Min. tržena količina | 1 | ||||||||
Valuta | USD | ||||||||
Kritje | 20% | ||||||||
Borza | United States of America | ||||||||
Provizija na trgovanje | 0% |
*Information provided by Capital.com
Predhodno. Zapri* | N/A |
Odpri* | N/A |
Enoletna sprememba* | N/A |
Dnevni razpon* | N/A |
Razpon 52 wk | 1.39-4.88 |
Povprečni obseg (10 dni) | 8,380.00 |
Povprečni obseg (3 meseci) | 460.81K |
Tržna kapitalizacija | 35.27M |
Razmerje P/E | -100.00K |
Število delnic v obtoku | 12.92M |
Prihodki | N/A |
EPS | -0.81 |
Dividenda (donosnost v %) | N/A |
Beta | -100.00K |
Datum naslednjega zaslužka | May 10, 2023 |
Vse podatke je zagotovil Refinitiv, razen podatkov, označenih z zvezdico, ki so *podatki, ki jih je zagotovil Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Zapiranje | Change | Change (%) | Odpiranje | High | Low |
---|
Monopar Therapeutics Inc. Events
Čas (UTC) (UTC) | Država | Dogodek |
---|---|---|
No events scheduled |
- Letni
- Četrtletno
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Skupni prihodki | 0 | 0 | 0 | 0 | 0 |
Prihodki | 0 | 0 | 0 | ||
Celotni odhodki iz poslovanja | 9.12725 | 6.50888 | 4.32376 | 3.33115 | 16.6031 |
Celotna prodaja/splošni/upravni stroški Odhodki | 2.63404 | 2.44368 | 2.35524 | 1.55669 | 1.16619 |
Raziskave in razvoj | 6.49321 | 4.0652 | 1.96852 | 1.77445 | 15.4369 |
Prihodki iz poslovanja | -9.12725 | -6.50888 | -4.32376 | -3.33115 | -16.6031 |
Prihodki (odhodki) od obresti, neto Neoperativni | 0.02402 | 0.0819 | 0.09889 | 0.10322 | 0.04826 |
Čisti dobiček pred obdavčitvijo | -9.10322 | -6.30457 | -4.22487 | -3.22793 | -16.5549 |
Čisti dobiček po davkih | -9.10322 | -6.30457 | -4.22487 | -3.22793 | -16.5549 |
Čisti dobiček pred dodatnimi postavkami | -9.10322 | -6.30457 | -4.22487 | -3.22793 | -16.5549 |
Čisti dobiček | -9.10322 | -6.30457 | -4.22487 | -3.22793 | -16.5549 |
Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -9.10322 | -6.30457 | -4.22487 | -3.22793 | -16.5549 |
Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -9.10322 | -6.30457 | -4.22487 | -3.22793 | -16.5549 |
Popravljen čisti dobiček | -9.10322 | -6.30457 | -4.22487 | -3.22793 | -16.5549 |
Popravljene ponderirane povprečne delnice | 12.4722 | 10.9583 | 10.421 | 10.421 | 10.421 |
Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -0.72988 | -0.57533 | -0.40542 | -0.30975 | -1.58861 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Popravljen normalizirani dobiček na enoto čistega dobička | -0.72988 | -0.57533 | -0.40542 | -0.30975 | -1.58861 |
Drugo, neto | 0 | 0.1224 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Skupni prihodki | 0 | 0 | 0 | 0 | 0 |
Celotni odhodki iz poslovanja | 2.45719 | 2.68112 | 2.45902 | 2.0924 | 1.89472 |
Celotna prodaja/splošni/upravni stroški Odhodki | 0.77925 | 0.69844 | 0.6317 | 0.61597 | 0.68794 |
Raziskave in razvoj | 1.67793 | 1.98268 | 1.82732 | 1.47643 | 1.20678 |
Prihodki iz poslovanja | -2.45719 | -2.68112 | -2.45902 | -2.0924 | -1.89472 |
Prihodki (odhodki) od obresti, neto Neoperativni | 0.00046 | 0.00053 | 0.00058 | 0.01223 | 0.0107 |
Čisti dobiček pred obdavčitvijo | -2.45672 | -2.68059 | -2.45844 | -2.08017 | -1.88402 |
Čisti dobiček po davkih | -2.45672 | -2.68059 | -2.45844 | -2.08017 | -1.88402 |
Čisti dobiček pred dodatnimi postavkami | -2.45672 | -2.68059 | -2.45844 | -2.08017 | -1.88402 |
Čisti dobiček | -2.45672 | -2.68059 | -2.45844 | -2.08017 | -1.88402 |
Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -2.45672 | -2.68059 | -2.45844 | -2.08017 | -1.88402 |
Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -2.45672 | -2.68059 | -2.45844 | -2.08017 | -1.88402 |
Popravljen čisti dobiček | -2.45672 | -2.68059 | -2.45844 | -2.08017 | -1.88402 |
Popravljene ponderirane povprečne delnice | 12.6044 | 12.5919 | 12.5827 | 12.5699 | 12.1394 |
Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -0.19491 | -0.21288 | -0.19538 | -0.16549 | -0.1552 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Popravljen normalizirani dobiček na enoto čistega dobička | -0.19491 | -0.21288 | -0.19538 | -0.16549 | -0.1552 |
- Letni
- Četrtletno
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Kratkoročna sredstva skupaj | 20.5216 | 16.7998 | 13.2296 | 7.25222 | 9.13124 |
Denarna sredstva in kratkoročne naložbe | 20.3039 | 16.7371 | 13.2139 | 6.89277 | 8.98189 |
Denarna sredstva in ustrezniki | 20.3039 | 16.7371 | 13.2139 | 6.89277 | 8.98189 |
Other Current Assets, Total | 0.21775 | 0.06269 | 0.01571 | 0.35945 | 0.14934 |
Total Assets | 20.5216 | 16.8687 | 13.352 | 7.31796 | 9.93127 |
Other Long Term Assets, Total | 0 | 0.06886 | 0.12238 | 0.06573 | 0.80003 |
Total Current Liabilities | 1.58054 | 1.17667 | 0.72417 | 0.39955 | 0.31187 |
Payable/Accrued | 1.58054 | 1.17667 | 0.72417 | 0.39955 | 0.31187 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.58054 | 1.17667 | 0.72417 | 0.39955 | 0.31187 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 18.9411 | 15.692 | 12.6279 | 6.9184 | 9.6194 |
Preferred Stock - Non Redeemable, Net | |||||
Common Stock | 0.0126 | 0.01145 | 0.01059 | 0.00929 | 0.00929 |
Additional Paid-In Capital | 60.22 | 47.8736 | 38.5088 | 28.5672 | 28.0379 |
Other Equity, Total | -0.00316 | -0.00787 | -0.01097 | -0.0024 | -18.4278 |
Total Liabilities & Shareholders’ Equity | 20.5216 | 16.8687 | 13.352 | 7.31796 | 9.93127 |
Total Common Shares Outstanding | 12.5981 | 11.4535 | 10.6215 | 10.421 | 10.421 |
Retained Earnings (Accumulated Deficit) | -41.2884 | -32.1852 | -25.8806 | -21.6557 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Kratkoročna sredstva skupaj | 18.0127 | 20.5216 | 22.4484 | 24.3884 | 25.8377 |
Denarna sredstva in kratkoročne naložbe | 17.819 | 20.3039 | 22.3416 | 24.2929 | 25.7231 |
Denarna sredstva in ustrezniki | 17.819 | 20.3039 | 22.3416 | 24.2929 | 25.7231 |
Other Current Assets, Total | 0.19364 | 0.21775 | 0.1068 | 0.09556 | 0.11457 |
Total Assets | 18.0664 | 20.5216 | 22.5172 | 24.4573 | 25.9065 |
Other Long Term Assets, Total | 0 | 0.06886 | 0.06886 | 0.06886 | |
Total Current Liabilities | 1.07412 | 1.58054 | 1.23994 | 1.10364 | 0.80627 |
Payable/Accrued | 1.04815 | 1.58054 | 1.23994 | 1.10364 | 0.80627 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.09946 | 1.58054 | 1.23994 | 1.10364 | 0.80627 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 16.9669 | 18.9411 | 21.2773 | 23.3536 | 25.1003 |
Common Stock | 0.01262 | 0.0126 | 0.01259 | 0.01258 | 0.01257 |
Additional Paid-In Capital | 60.7031 | 60.22 | 59.8776 | 59.4955 | 59.162 |
Retained Earnings (Accumulated Deficit) | -43.7451 | -41.2884 | -38.6078 | -36.1493 | -34.0692 |
Other Equity, Total | -0.00374 | -0.00316 | -0.00515 | -0.00516 | -0.0051 |
Total Liabilities & Shareholders’ Equity | 18.0664 | 20.5216 | 22.5172 | 24.4573 | 25.9065 |
Total Common Shares Outstanding | 12.6206 | 12.5981 | 12.5906 | 12.5827 | 12.5699 |
Property/Plant/Equipment, Total - Net | 0.05369 | ||||
Accrued Expenses | 0.02598 | ||||
Other Liabilities, Total | 0.02534 |
- Letni
- Četrtletno
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Čisti prihodki/začetna postavka | -9.10322 | -6.30457 | -4.22487 | -3.22793 | -16.5549 |
Denarna sredstva iz poslovanja | -7.3174 | -4.66227 | -3.01768 | -2.68049 | -2.62747 |
Nedenarne postavke | 1.46805 | 1.19849 | 1.01117 | 0.52933 | 13.8068 |
Spremembe v obratnem kapitalu | 0.31777 | 0.44381 | 0.19602 | 0.01811 | 0.12058 |
Denarna sredstva pri financiranju | 10.8795 | 8.18212 | 9.34741 | -0.20627 | 9.53639 |
Postavke denarnega toka pri financiranju | -0.06325 | -0.11557 | -0.98481 | -0.20627 | 4.83074 |
Izdaja (odplačilo) delnic, neto | 10.9428 | 8.17529 | 10.3322 | 0 | 4.70565 |
Neto sprememba denarnih sredstev | 3.56676 | 3.52318 | 6.32116 | -2.88915 | 6.90892 |
Učinki deviznih tečajev | 0.00462 | 0.00333 | -0.00857 | -0.0024 | |
Cash Taxes Paid | 0 | -0.0111 | |||
Izdaja (odplačilo) dolga, neto | 0.1224 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -2.45672 | -9.10322 | -6.42263 | -3.96419 | -1.88402 |
Cash From Operating Activities | -2.4675 | -7.3174 | -5.2855 | -3.34418 | -1.93806 |
Non-Cash Items | 0.49981 | 1.46805 | 1.11789 | 0.72583 | 0.36823 |
Changes in Working Capital | -0.51059 | 0.31777 | 0.01925 | -0.10582 | -0.42227 |
Cash From Financing Activities | -0.01667 | 10.8795 | 10.8873 | 10.8973 | 10.9213 |
Financing Cash Flow Items | -0.01667 | -0.06325 | -0.05548 | -0.0455 | -0.0215 |
Issuance (Retirement) of Stock, Net | 0 | 10.9428 | 10.9428 | 10.9428 | 10.9428 |
Foreign Exchange Effects | -0.00066 | 0.00462 | 0.00264 | 0.00263 | 0.00277 |
Net Change in Cash | -2.48483 | 3.56676 | 5.60446 | 7.55574 | 8.986 |
Issuance (Retirement) of Debt, Net | 0 | 0 |
Ime vlagatelja | Vrsta vlagatelja | Odstotek neporavnanih obveznosti | Delnice v lasti | Sprememba delnic | Datum imetništva | Ocena prometa |
---|---|---|---|---|---|---|
Tacticgem LLC | Corporation | 31.8202 | 4111273 | 0 | 2022-04-15 | LOW |
Gem Pharmaceuticals LLC | Corporation | 23.648 | 3055394 | 0 | 2022-04-15 | LOW |
Hendricks (Diane) | Individual Investor | 3.628 | 468750 | 0 | 2022-04-15 | LOW |
Brown Michael J | Individual Investor | 1.7471 | 225730 | 2859 | 2022-12-31 | LOW |
Tactic Pharma LLC | Corporation | 1.29 | 166667 | 0 | 2022-04-15 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.7738 | 99976 | 97 | 2022-12-31 | LOW |
Robinson (Chandler D) | Individual Investor | 0.5939 | 76730 | 4396 | 2023-01-01 | LOW |
Starr (Christopher M) | Individual Investor | 0.5041 | 65130 | 2859 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3242 | 41892 | 2721 | 2022-12-31 | LOW |
Cittadine (Andrew) | Individual Investor | 0.2082 | 26894 | 2656 | 2022-12-31 | HIGH |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1771 | 22884 | -293 | 2022-12-31 | LOW |
Mazar (Andrew Paul) | Individual Investor | 0.1712 | 22125 | 0 | 2022-04-15 | LOW |
Klausner (Arthur J) | Individual Investor | 0.1604 | 20730 | 2859 | 2022-12-31 | LOW |
Tsuchimoto (Kim R) | Individual Investor | 0.1432 | 18507 | 728 | 2023-01-01 | MED |
Anderson (Raymond William) | Individual Investor | 0.1295 | 16730 | 2859 | 2022-12-31 | MED |
Northern Trust Global Investments | Investment Advisor | 0.1021 | 13197 | 0 | 2022-12-31 | LOW |
Morgan Stanley Smith Barney LLC | Investment Advisor | 0.031 | 4000 | 0 | 2022-12-31 | LOW |
UBS Financial Services, Inc. | Investment Advisor | 0.0244 | 3154 | -2245 | 2022-12-31 | LOW |
Tower Research Capital LLC | Hedge Fund | 0.0219 | 2831 | -300 | 2022-12-31 | HIGH |
Paragon Wealth Strategies, LLC | Investment Advisor | 0.0004 | 58 | 0 | 2022-12-31 | HIGH |
Zakaj izbrati Capital.com? Številke govorijo same zase.
Capital.com Group500K+
Borzni posredniki
92K+
Aktivne stranke mesečno
$53M+
Mesečni obseg naložb
$30M+
Dvigi vsak mesec
Kalkulator trgovanja
Izračunajte svoj hipotetični P&L, če bi trgovino s CFD odprli na določen datum (izberite datum) in jo zaprli na drug datum (izberite datum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Monopar Therapeutics Inc. Company profile
O družbi Monopar Therapeutics Inc.
Monopar Therapeutics Inc. je biofarmacevtsko podjetje v klinični fazi. Podjetje se osredotoča predvsem na razvoj terapevtskih zdravil, namenjenih bolnikom z rakom. Njen proizvodni program vključuje zdravila Validive, camsirubicin, MNPR-101 in MNPR-202. Zdravilo Validive je prva mukoadhezivna bukalna tableta v svojem razredu za preprečevanje hudega oralnega mukozitisa (SOM), povzročenega z obsevanjem, pri bolnikih z rakom orofarinksa. Njegov camsirubicin je nov analog doksorubicina s selektivno topoizomerazo II-alfa, ki je v klinični fazi razvoja posebej zasnovan tako, da ohranja protirakavo delovanje in hkrati zmanjšuje toksične učinke na srce. MNPR-101 je humanizirano monoklonsko protitelo, ki je zasnovano tako, da se veže na specifičen celični površinski receptor, ki ga najdemo na rakavih celicah, receptor za aktivator plazminogena urokinaze (uPAR), in prekine več poti, potrebnih za rast in napredovanje tumorja. MNPR-202 je analog kambirubicina v zgodnji fazi zdravljenja različnih vrst raka.
Industry: | Biotechnology & Medical Research (NEC) |
1000 Skokie Blvd Ste 350
WILMETTE
ILLINOIS 60091-1146
US
Izkaz poslovnega izida
- Annual
- Quarterly
Ljudje gledajo tudi
Še vedno iščete posrednika, ki mu lahko zaupate?
Pridružite se 500.000+ trgovcem po vsem svetu, ki so se odločili za trgovanje s Capital.com